Miranda Jayne Toledano - 14 Jul 2026 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ENTX
Reported as of: 14 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jul 2026, 16:05:27 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact

Key filing fact

Miranda Jayne Toledano filed Form 4 for Entera Bio Ltd. (ENTX) on 16 Jul 2026.

Key facts

This page summarizes Miranda Jayne Toledano's Form 4 filing for Entera Bio Ltd. (ENTX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 16 Jul 2026, 16:05.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001686530 Primary reporting owner

Toledano Miranda Jayne

Relationship: Chief Executive Officer, Director
Address: KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR, JERUSALEM, ISRAEL
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Signature date: 16 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENTX transaction

Ordinary Shares, par value NIS 0.0000769 per share

Award

Transaction value
Shares: +347,567
Change %: +81%
Price: $0.000000^*
Shares after: 774,142
Date: 14 Jul 2026
Ownership: Direct
Footnotes: F1

ENTX transaction

Ordinary Shares, par value NIS 0.0000769 per share

Award

Transaction value
Shares: +72,993
Change %: +9.4%
Price: $0.000000^*
Shares after: 847,135
Date: 14 Jul 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to approval by the Company's shareholders, which was obtained on July 14, 2026. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2025 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).

Footnote F2

Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board on May 7, 2026, subject to approval by the Company's shareholders, which was obtained on July 14, 2026. This grant was awarded to the Reporting Person in lieu of $100,000 the Reporting Person is entitled to under the Reporting Person's base salary for 2026. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).